Sign In
Buy DNL
$45.39
-0.440 (-0.96%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the publication of results from the open-label Phase 1/2 clinical trial of its in
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment
02:47pm, Wednesday, 10'th Dec 2025
Denali Therapeutics Inc. is maintained at a Strong Buy rating, driven by progress in its MPS II [Hunter Syndrome] program with tividenofusp alfa. Despite discontinuing ALS efforts, DNLI's BLA for tivi
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
07:21am, Wednesday, 01'st Oct 2025
The WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) was launched on 06/16/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the World ETFs category of the
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
07:21am, Friday, 01'st Aug 2025
A smart beta exchange traded fund, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) debuted on 06/16/2006, and offers broad exposure to the World ETFs category of the market.
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
07:21am, Thursday, 29'th May 2025
Launched on 06/16/2006, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund offering broad exposure to the World ETFs category of the market.
DNL: Lagging Its Peers For A While
08:14am, Monday, 14'th Apr 2025
WisdomTree Global ex‐U.S. Quality Dividend Growth Fund holds 300 ex-US dividend stocks, focusing on quality and growth metrics. DNL is diversified across holdings, sectors, and countries, with signi
SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the company's initiation of a rolling submission of a biologics license ap
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
07:21am, Tuesday, 25'th Mar 2025
Designed to provide broad exposure to the World ETFs category of the market, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund launched on 06/16/2006
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
02:16pm, Thursday, 20'th Mar 2025
Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 sh
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
07:23am, Monday, 20'th Jan 2025
Designed to provide broad exposure to the World ETFs category of the market, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund launched on 06/16/2006
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platfor
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
07:20am, Tuesday, 19'th Nov 2024
Designed to provide broad exposure to the World ETFs category of the market, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund launched on 06/16/2006
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
07:21am, Tuesday, 17'th Sep 2024
Launched on 06/16/2006, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund offering broad exposure to the World ETFs category of the market.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation a
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
10:55pm, Monday, 19'th Aug 2024
Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS a
